TCT-32 Prospective, Multi-Center Evaluation of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold: Imaging Outcomes and 4-Year Clinical and Imaging Results

Verheye, Stefan; Schofer, Joachim; Mæng, Michael; Witzenbichler, Bernhard; Botelho, Roberto; Ormiston, John A.; Costa, Ricardo; Costa, José de Ribamar; Chamié, Daniel; Castro, Juliana P.; Abizaid, Andréa; Yan, John; Bbhat, Vinayak; Morrison, Lynn; Toyloy, Sara; Abizaid, Alexandre

doi:10.1016/j.jacc.2016.09.053

Search citation statements

Order By: Relevance

Paper Sections

Select...

Future Perspective1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DESolve Nx clinical study (3,17) expansion, increase of scaffold embedding into the vessel) and enhanced visibility angiography. It is pre-mounted in a dedicated balloon, the TRASFORM balloon which is characterized by a central segment expansion 0.25 mm larger than the end segments (3 mm) at nominal pressure.…”

Section: Future Perspectivementioning

confidence: 99%

The DESolve novolimus bioresorbable Scaffold: from bench to bedside

Mattesini¹,

Bartolini²,

Dini³

et al. 2017

J. Thorac. Dis.

View full text Add to dashboard Cite

Abstract:The DESolve (Elixir Medical Corporation, Sunnyvale, California, USA) is a poly-L lactidebased polymer scaffold coated with the antiproliferative and anti-inflammatory drug novolimus. The scaffold biodegrades within one year with a complete resorption in two years and in vitro bench test have shown the ability to supply the necessary radial strength to support the vessel for the critical 3-to 4-month period after implant. The DESolve showed the unique self-correction property, which may reduce the incidence of minor malapposition after deployment. Overexpansion with DESolve is safe since a high capability resistance to fracture has been demonstrated with this scaffold. The aim of this review is to provide a comprehensive overview of the available preclinical and clinical data regarding the DESolve.

show abstract

Section: Future Perspectivementioning

confidence: 99%